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Summary Single-chain urokinase-type plasminogen activator (pro-uPA) is bound to a specific surface recep-
tor on ovarian cancer HOC-I cells that is incompletely saturated. Saturation of uncovered receptors by uPA
polypeptides with intact amino-terminal fragment (ATF) derived from pro-uPA by limited proteolysis (human
leucocyte elastase [HLE] or V8 protease) has been studied. HOC-I cells preferentially invaded reconstituted
basement membranes in a time- and plasminogen-dependent manner. This process was inhibitable by prein-
cubation with uPA polypeptides in the medium at levels which suggested that complete saturation of cell
surface uPA receptors occurred. This result indicates that occupation of uPA receptors by enzymatically
inactive uPA fragments or prevention of rebinding of pro-uPA synthesised by tumour cells to the receptors
specifically reduces the invasion of the tumour cells through basement membranes in vitro.
Cancer cells produce and secrete urokinase-type plasminogen
activator (uPA) in an enzymatically inactive proenzyme form
(single-chain uPA; pro-uPA) (Dano et al., 1985; Stoppelli et
al., 1985). Secreted pro-uPA can immediately bind to the
specific uPA receptors on tumour cell surfaces with high
affinity. The receptor-bound pro-uPA may be converted to
the enzymatically active two-chain uPA (high molecular
weight-uPA; HMW-uPA) by the proteinases plasmin, kal-
likrein, or cell surface-associated cathepsin B (Cubellis et al.,
1986; Estreicher et al., 1989; Kobayashi et al., 1991). The
initial activation of receptor-bound pro-uPA with subsequent
activation of plasminogen and procollagenase on the tumour
cell surfaces may be required for the proteolytic degradation
of tumour stromas and basement membranes (Liotta et al.,
1983; Mignatti et al., 1986). It has been demonstrated that
cell-associated uPA is not sensitive to specific plasminogen
activator inhibitors (Stoppelli et al., 1986). Thus the uPA
receptor focusses the proteolytic activity of uPA to the cancer
cell surface. The increased invasive potential of tumour cells
is correlated well with cell surface-associated proteolytic
activity due to the interaction between uPA and its surface
receptor. Evidence for the role of an uPA-plasmin-
collagenase activation cascade in cancer cells is provided
(Mignatti et al., 1986). The constitutive saturation of uPA
receptors with pro-uPA synthesised by the same cell may be
a property of tumour cells, providing a mechanism for their
invasiveness (Stoppelli et al., 1986).
The receptor-binding domain within the uPA-molecule has
been localised to the amino acid sequence 18-32 of the
amino-terminal fragment (ATF) of uPA (Appella et al.,
1987). ATF comprising the so called Growth Factor-like
domain (GFD) and the Kringle has been shown to bind to
uPA receptors on normal and neoplastic cells with the same
affinity as pro-uPA (Vassalli et al., 1985; DelRosso et al.,
1985; Cubellis et al., 1986; Appella et al., 1987; Estreicher et
al., 1989; Stephens et al., 1989; Picone et al., 1989). ATF,
lacking the B-chain, does not show enzymatic activity (Stop-
pelli et al., 1985; Cubellis et al., 1986). If all membrane
receptor sites are occupied by enzymatically inactive uPA
fragments such as GFD or ATF, pro-uPA synthesised by
tumour cells can not bind to their own receptors any more,
because tumour cells do not have free uPA binding sites. In
this situation, proteolytic activity attributable to uPA on
tumour cell surface would be lost as the number of free
binding sites decreased.
Various test systems have been devised to study the
mechanism of invasiveness and inhibition of experimental
metastasis in vitro. These have suggested that proteinase
inhibitors and specific antibodies for collagenase, uPA and
plasmin prevented cancer cell invasion of chick chorioallan-
toic membrane (Ossowski & Reich, 1980; Ossowski & Reich,
1983; Ossowski, 1988), human amnion (Mignatti et al., 1986),
and reconstituted basement membranes (Gehlsen et al., 1984;
Kleinman et al., 1986; Terranova et al., 1986; Albini et al.,
1987). The aim of this study is to determine (1) how to
obtain uPA fragments/polypeptides with intact GFD by
limited proteolysis, and (2) whether uPA polypeptides with
intact GFD can inhibit HOC-I tumour cell invasion in an in
vitro reconstituted basement membrane assay.
Materials and methods
Interaction ofpro-uPA with severalproteinases
Pro-uPA (Saruplase, Grunenthal GmbH, Stolberg, FRG;
Green Cross, Co., Japan) was incubated with human
leucocyte elastase (HLE) or V8 protease, if not otherwise
specified, at a molar ratio of 4:1 or 50:1, respectively, as a
function of time at 37TC in phosphate buffered saline, pH 7.4
(PBS). In order to obtain plasmin-treated ATF, pro-uPA was
first incubated (6 h, 37C) with a 10-fold lower concentration
(molar ratio) of plasmin in 50 mM phosphate buffer,
0.1 M NaCl, pH 6.0. Subsequently, this pro-uPA/plasmin
solution was adjusted to pH 8.0 and then further incubated
(12 h, 37'C). The ATF formed was separated from LMW-
uPA by ion exchange column chromatography (Gunzler et
al., 1982). The subfragments of the ATF polypeptides with
intact GFD of pro-uPA were obtained by limited proteolysis
with HLE or V8 protease, while ATF with cleaved GFD was
obtained by plasmin treatment.
SDS-PAGE and Western blot
Pro-uPA (1OitM) was incubated with HLE (2.5tM), V8 pro-
tease (0.2pM), or plasmin (lIpM) in PBS as described above.
At indicated intervals, an aliquot was removed and added to
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an aliquot of sample buffer (0.5 M Tris-HCl, pH 6.8, 2.5%
SDS, 25% glycerol, with and without 5% 2-mercapto-
ethanol), boiling for 3 min, and then immediately analysed
by 5-15% sodium dodecyl sulfate-poly acrylamide gel elect-
rophoresis (SDS-PAGE) (Laemmli, 1970). Proteins separated
by SDS-PAGE were electroblotted onto polyvinylidine
difluoride (PVDF) membrane (Millipore, Bedford, MA),
using a semidry electroblotting apparatus (Parmacia-LKB) at
40 mA/gel (90 min, 23°C). After transfer, the sheets were
incubated with mouse monoclonal antibody (moAB) 377
(1.0jig ml-'), reacting with the A-chain of pro-uPA, moAB
GFDl (0.45 pg ml-'), specific for a peptide sequence within
Growth Factor-like domain (GFD) of uPA, and moAB 98.6
(0.51Agml-'), reacting with the B-chain of pro-uPA in Tris-
buffered saline containing 2% BSA, pH 7.5 (TBS-BSA) (1 h,
23°C). The sheets were incubated with biotin-conjugated anti-
mouse IgG (0.5fg ml-', Sigma) in TBS-BSA (1 h, 23°C),
followed by incubation with avidin-peroxidase (4jsg ml-',
Sigma) in TBS-BSA (1 h, 23°C), and developed with 0.1%
4-chloro-l-naphthol, 37% ethanol, 0.005% hydrogen perox-
ide in TBS.
Isolation ofthe ATF-fractionsfrom HLE-, V8 protease-, or
plasmin-treatedpro-uPA
Crude ATF-fraction of uPA-molecule was first obtained as a
side-fraction by the same method as the preparation of two-
chain uPA/LMW-uPA by plasmin (Gunzler et al., 1982). The
ATF polypeptide formed was separated from two-chain
uPA/LMW-uPA by ion-exchange column chromatography.
Two mg crude ATF-fraction was subjected to cation-
exchange chromatography Mono S HR 5/5 column applying
a HPLC-system equilibrated with 50 mm sodium acetate
buffer, pH 5.0. After washing with equilibrating buffer,
bound proteins were eluted with a linear salt gradient
(0.15-0.5M NaCI) in sodium acetate buffer for 35 min at
23°C. Further purification was achieved by reversed-phase
HPLC. Polypeptides were eluted with a linear gradient from
0 to 70% acetonitrile in 0.1% trifluoro-acetic acid/H20.
Synthesis ofuPA peptides
uPA20-30 (consisting of amino acid sequences from Val20
to Tyr3O of uPA molecule) and uPA17-34 (from Glyl7 to
Pro34), representing sequences within the GFD of uPA, were
synthesised by the Merrifield-solid-phase method. These syn-
thetic peptides were purified to homogeneity by reversed-
phase HPLC.
N-terminal amino acid sequence determination and amino acid
analysis
The proteinase-mediated cleavage site in pro-uPA was deter-
mined by N-terminal amino acid sequence analysis (Schmitt
et al., 1989). Separated uPA polypeptides were subjected to
six Edman degradation cycles. Sequence analyses were per-
formed with a Beckman 890C spinning cup sequenator.
Cells and culture
Ovarian cancer cell line, designated as HOC-I, was estab-
lished from a recurrent region of ovarian endometrioid car-
cinoma (Fujii, 1989). The cells were maintained under an
atmosphere of 5% CO2 in RPMI 1640 medium supplemented
with 10% foetal calf serum (FCS; GIBCO). The addition of
purified human plasminogen (100figml-'; Sigma) to HOC-I
cells produced significant increases in the specific activity of
cell-associated urokinase-type plasminogen activator (uPA),
indicating that the HOC-I cells express enzymatically inactive
uPA (pro-uPA) on their cellular surfaces, which is cleaved by
trace contamination of plasmin in the plasminogen prepara-
tion (Stoppelli et al., 1986).
U937 promyeloid cells were grown in RPMI 1640 medium
supplemented with 10% FCS. Differentiated U937 cells were
obtained by incubation in the above medium containing IM
phorbol 12-myristate-13-acetate (PMA). A 3-day incubation
period resulted in 60% adherent cells. Adherent cells were
detached with PBS containing 1 mM EDTA, harvested by
centrifugation (1,200 rpm, 10 min), and used for the binding
and competition experiments (Kobayashi et al., 1991).
Quantitative assessment ofbinding ofuPA polypeptides to the
uPA receptor on PMA-stimulated U937 cells byflow
cytometry (FCM).
FCM can substitute for radioisotope binding techniques in
order to investigate the structure-function relationship of
uPA receptor binding site (Kobayashi et al., 1991). PMA-
stimulated U937 cells were treated with 50 mM glycine HCI,
0.5 M NaCl, pH 3.0, first, to dissociate receptor-bound uPA.
After centrifugation, the cell pellet was adjusted to a density
of 106 cells ml-' in PBS containing 0.1% BSA, pH 7.4 (PBS-
BSA). uPA polypeptides derived from pro-uPA by limited
proteolysis were used as competitors. 1.5 nM of FITC-pro-
uPA in the presence or absence of unlabelled competitors
was added to the cells (30 min, 4°C). Nonspecific binding of
FITC-pro-uPA to U937 cells was determined in the presence
of an excess (O.IlfM) of parent pro-uPA.
Cell attachment assay
The fibronectin solution (10 tLgml-' PBS) was incubated in
the 96-well microtiter plate (Costar, Cambridge, MA; 2 h,
23°C) (Ruoslahti et al., 1982). The unattached protein was
removed by washing three times with PBS. For the assay, the
HOC-I cells were washed three times with PBS-BSA, then
1 mm EDTA was added, and the cells were removed by
agitation until they were detached. The cells were then col-
lected by centrifugation, washed with PBS-BSA, and were
dispersed by pipetting until a single cell suspension was
obtained. Before the last centrifugation, a sample was taken,
and cell numbers and viability by trypan blue exclusion were
determined. The cells are suspended in PBS-BSA at a concen-
tration of 2 x 106 cells ml '. One hundred tlI of RPMI 1640
containing plasminogen (100 lgml-') in the absence or
presence of uPA polypeptides, as described in the Figure 9
legend, was added to each well (1 h, 37°C). This was followed
by the addition of 1001gl of the cell suspension. After the
plate is incubated (2 h, 37°C), the unattached cells are
removed simply by tossing out the medium and washing.
Under optimal conditions, about 70% of these cells remain
attached to the well after washing (Control). The cells are
then fixed with 3% paraformaldehyde and stained with 1%
toluidine blue, 3% formaldehyde in PBS, and attached cells
are counted with an Olympus light microscope ( x 200). The
data are expressed as the number of attached cells at ran-
domly chosen area (each sample was assayed using triplicate
wells and each well was counted in three areas).
Cell invasion assay
Invasiveness of tumour cells was determined using a
modification of the Membrane Invasion Culture System
(MICS) (Gehlsen et al., 1984; Kleinman et al., 1986; Ter-
ranova et al., Albini et al., 1987). Briefly, polycarbonate
filters, 8-,sm pore size (Costar) were coated with an extract of
basement membrane components (Matrigel, 50ptg/filter, 1.2 gtg mm-2) and dried (2 h, 37°C). Blind well Boyden
chambers were filled with 600 1l RPMI 1640, 0.1% BSA in
the lower compartment and coated filters mounted in the
chamber. The cells to be studied were collected by short
exposure to EDTA resuspended in PBS-BSA, and shaking as
described above. The in vitro cell invasion assay was carried
out to study the role of cell-associated uPA in tumour cell
invasion by attempting to saturate uncovered uPA receptors
by ATF or enzymatically inactive uPA polypeptides (modify-
ing agents). We added these modifying agents under the
conditions described below. The HOC-I cells were pretreated
with each modifying agent (at the concentrations noted) as
described in the Figure 8 legend, typically for 60 min at 23°C.AMINO-TERMINAL FRAGMENTS AND TUMOUR CELL INVASION 539
Then 100 ,il cell suspension (2 x 106 ml-') was placed in the
upper compartment of the chamber and followed by the
addition of 100pl serum-free medium in the presence of
plasminogen (100ligml-'). Human fibroblast conditioned
media were placed in the lower compartment as a source of
chemoattractants. Under these conditions, few cells died
within 24 h in preliminary experiments. The chemotactic
assays were conducted in a similar fashion without coating of
Matrigel. After incubation (24 h, 37°C) the filters were then
removed, fixed and stained. All material from the upper
surface of the filter was carefully removed by scraping with a
cotton tip, and invasive cells adhering to the lower surface of
the filter were quantitated with a light microscope ( x 200).
The data are expressed as the number of cells on the bottom
surface of the filter at randomly chosen area (each sample
was assayed using triplicate filters and filters were counted in
three areas).
Results
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Figure 1 SDS-PAGE and Western blot: specific cleave of
uPA by human leucocyte elastase. SDS-PAGE (a, 15% al
amide, nonreducing conditions) of pro-uPA treated with HL
37'C for different lengths of time. Lane 1, 0 min; lane 2, 10
lane 3, 30 min; lane 4, 1 h; lane 5, 3 h; lane 6, 5 h; lane 7,
lane 8, 24 h. Western blot with moAB 377 (b, reacting
A-chain of uPA) and moAB GFD1 (c, reacting with the rece
binding epitope uPA17-34 within the GFD of uPA). Ai
indicates ATF[HLE] with molecular mass of 20 KDa.
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uPA polypeptides derivedfrom pro-uPA by limitedproteolysis
a ofproteinases
Incubation of pro-uPA with HLE results in the cleavage of
uPA at amino acid position 160 and 166, generating
enzymatically inactive two-chain uPA (Schmitt et al., 1989).
Extensive treatment (96 h, 23°C) of pro-uPA with HLE
results in production of two-chain uPA and lower molecular
mass uPA fragments (molecular mass = 20 KDa and 14
KDa). Pro-uPA incubated with HLE was analysed by SDS-
b PAGE and also by Western blot (Figure 1). The 20 KDa and
the 14 KDa polypeptides were obtained as a side-fraction by
the preparation of two-chain uPA. When the 20 KDa poly-
peptide were chromatographed by cation-exchange on a
Mono S column, one major peptide peak associated with
three minor peaks were separated (Figure 2, C-3). A major
peptide (designated as ATF[HLE]) further purified by
reversed phase HPLC reacts with both moAB 377 and moAB
GFD1, while three minor peptides react mainly with moAB
GFD1 (by Western blot and Dot blot analysis). The 14 KDa
c uPA fragment reacts with moAB 98.6, suggesting that this
peptide is a degradation product of the B-chain of uPA.
Under reducing conditions, the ATF[HLE] showed a single
band on SDS-PAGE with a molecular mass of 17 KDa,
suggesting that this polypeptide is not a single-chain uPA
polypeptide, but consists of the GFD that was not cleaved.
Proteolysis of pro-uPA with V8 protease was visualized by
SDS-PAGE and Western blot. The time course digestion was
monitored by SDS-PAGE under nonreducing conditions
(Figure 3). Virtually complete proteolysis was obtained with
3 h, yielding four major polypeptides with molecular mass of
pro- 38 KDa, 33 KDa, 13 KDa and 12 KDa as well as two minor
Lcryl- polypeptides with molecular mass of 17 KDa and 5 KDa.
,E at The results of Western blot analyses are illustrated in Figure
min; 3. MoAB GFD1 reacts with pro-uPA/two-chain uPA and the
8 h; polypeptide bands at 38 KDa, 17 KDa and 5 KDa. MoAB
with GFD1 does not react with the polypeptide bands at 33 KDa, ptor 13 KDa and 12 KDa. MoAB 377 reacts with pro-uPA/two-
chain uPA and the polypeptides including 38 KDa, 17 KDa,
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Figure 2 Comparison by Western blot analysis of uPA polypeptides obtained after treatment of pro-uPA by human leucocyte
elastase. Various degradation products of pro-uPA were identified by the Western blot technique. a and b, Coomassie blue stain
(SDS-PAGE); c and d, western blot with moAB 377 (1), moAB 98.6 (2, reacting with B-chain of uPA), and moAB GFDI. (3). a
and c, nonreducing conditions; b and d, reducing conditions. Arrows indicate two-chain uPA a, B-chain, A-chain, ATF[HLE] (b,
from the top), two-chin uPA (c,l), B-chain (d,2), and A-chain, ATF[HLE] (d,3; from the top).540 H. KOBAYASHI et al.
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Figure 3 SDS-PAGE and Western blot: specific cleavage of
pro-uPA by V8 protease. SDS-PAGE (a, 15% acrylamide,
nonreducing conditions) of pro-uPA treated with V8 protease at
37°C for different lengths of time. Lane 1, 0 min; lane 3, 5 min;
lane 4, 40 min; lane 5, 3 h; lane 6, 5 h, lane 7, 8 h, lane 8, 24 h;
lane 2, ATF[PL] derived from plasmin-treated pro-uPA. See
Figure 5. Western blot with moAB 377 b and moAB GFD1 c.
Arrows indicate ATF[V8] (a, lane 4), uPA44- 135<52/53>,
uPA44-135, uPA4-43 (a, lane 8; from the top), ATF[V8],
uPA44-135<52/53>, uPA44-135 (b, lane 4; from the top),
ATF[V8], uPA4-43 (c, lane 4; from the top).
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Figure 4 Comparison by dot blot analysis of isolated uPA
polypeptides obtained after treatment of pro-uPA by V8 pro-
tease. The crude ATF-fraction separated from two-chain uPA by
ion-exchange column chromatography was subjected to Mono S
.column applying a HPLC-system. Further purification was
achieved by reversed-phase HPLC. 1, ATF[V8]; 2, uPA4-43; 3,
uPA44-135<52/53>; 4, uPA44-135. Dot blot with moAB
GFD1 a and moAB 377 b.
13 KDa, and 12 KDa. Under reducing conditions, the
molecular mass of the uPA polypeptide (designated as
ATF[V8]) was found to be 17 KDa (data not shown), sugges-
ting that this polypeptide is a single-chain polypeptide consis-
ting of the intact GFD. Regarding the uPA fragment with
molecular mass of 13 KDa, under reducing conditions, the
molecular mass was found to be 12 KDa due to the removal
of the N-terminal amino acid residues Ile44-Glu52. This
finding is based on amino acid composition analyses and
N-terminal amino acid sequence analyses of the polypeptide
(data not shown). Two sequences in an approximately 1:1
ratio were found; the first started with Ile44 (uPA44-52), the
second from Gly53 (uPA53-135). Therefore this polypeptide
was found to consist of the Kringle that was cleaved between
the Glu52 and Gly53 bond (designated as a uPA44-
135<52/53>). Regarding the uPA fragment with molecular
mass of 12 KDa, under reducing conditions, the molecular
mass was found to be the same. This polypeptide was found
to consist of the Kringle that was not cleaved (uPA44-135).
Also, the uPA fragment with molecular mass of 5 KDa was
found to consist of the intact GFD (uPA4-43). MoAB 377
does not react with this polypeptide, while moAB GFDI
Kringle-domain
70
Figure 5 Schematic representation of the pro-uPA molecule and its cleavage sites. Proteolytic cleavage at peptide bond
Lysl58-Ilel59 yields the enzymatically active two-chin uPA-molecule (HMW-uPA) still held together by the disulfide bonds. If
pro-uPA, HMW-uPA, and ATF are cleaved within the peptide sequence 20-30, binding to uPA-receptor will not occur. Proteolytic
degradations of pro-uPA by other proteinases are described in detail in the reference (Schmitt et al., 1991). Plasmin (P), V8
protease (V), elastase (E).AMINO-TERMINAL FRAGMENTS AND TUMOUR CELL INVASION 541
reacts (Figure 4). The locations of the respective cleavage
sites are illustrated in Figure 5. Limited proteolysis of pro-
uPA with plasmin at pH 6.0 and subsequent incubation at
pH 8.0 (autodigestion) results in the cleavage of HMW-uPA
at amino acid position 135, generating LMW-uPA and ATF
(designated at ATF[PL] (Stoppelli et al., 1985; Cubellis et al.,
1986)) (Figure 6). ATF[PL] contains an additional three
polypeptides (see Kobayashi et al., 1992a). One represents
the intact Kringle (Ser47-Lysl35), one ATF with proteolytic
cleavage occurring at Lys23-Tyr24 (uPAl- 135<23/24>)
and the remaining fragment ATF with proteolytic cleavage,
both at Lys23-Tyr24 and at Lys35-Lys36 (uPAl-135<23/
24, 35/36>). The amount of intact ATF contained in the
crude ATF preparation (ATF[PL]) separated from LMW-
uPA is very low (1-2%) (Kobayashi et al., 1992a).
Binding ofuPA polypeptides to the U937 cell receptor assessed
byflow cytometry
Competitive inhibition assays employing flow cytometry
(FCM) were performed to examine the affinity of each uPA
polypeptide responsible for binding to the uPA receptor on
U937 cells. Pro-uPA, HMW-uPA, uPA polypeptides (ATF
[HLE], ATF[V8], ATF[PL], uPA4-43, uPA44-135, uPA44-
135<52/53>, uPA47-135, uPAl-135<23/24>, and
uPAl-135<23/24, 35/36>), and synthetic uPA peptides
(uPA20-30 and uPA17-34) were tested for binding to recep-
tors on U937 cells. The results of experiments using PMA-
stimulated adherent cells are shown in Figure 7. 50% inhibi-
tion of FITC-pro-uPA binding to U937 cells was obtained
with 1.5 nM pro-uPA, 3.0 nM HMW-uPA, 12 nM ATF[V8],
20 nM ATF[HLE], 70 nM uPA4-43, 1000 nM uPA20-30,
1000 nM uPA17-34, and> 1,000 nM ATF[PL], respectively.
Synthetic uPA peptides have an affinity for the uPA receptor
about 667-fold less than pro-uPA as the secondary structure
stabilised by the cystein bridges is lost. Also, ATF[PL] has an
affinity for the uPA receptor of at least 667-fold less than
pro-uPA itself. uPA fragments not containing GFD
(uPA44-135, uPA44- 135 <52/53>, uPA47-135) and ATF
with an additional proteolytic cleavage (uPAl -135<23/
24>, uPAI-135<23/24,35/36>) do not bind to the recep-
tor.
Effect ofuPA polypeptides on cancer cell invasion
If a cell-associated uPA is essential to the invasion process of
cancer cells, an inhibition of invasion would be observed
after all membrane receptor sites are occupied by
enzymatically inactive uPA fragments such as GFD or ATF.
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Figure 6 SDS-PAGE and Western blot: Specific cleavage of
pro-uPA by plasmin. SDS-PAGE (a, 15% acrylamide, nonreduc-
ing conditions) or pro-uPA treated with plasmin at 37'C for
different lengths of time. Lane 1, 0 min; lane 2, 10 min; lane 3,
30min; lane 4 1 h; lane 5, 5 h; lane 6, 24 h; lane 7, 96 h; lane 8,
ATF[PL]. Western blot with moAB 377 b and moAB GFD1 c.
Each arrow indicates that LMW-uPA (lane 7), ATF (mixture of
uPAl-135<23/24> and uPAl-135<23/24, 35/36>) and
Kringle-domain (uPA47-135) (lane 8; from the top).
Under this condition, pro-uPA synthesised and released by
tumour cells can not bind to their own receptors, because
tumour cells do not have free uPA binding sites. Experiments
with uPA polypeptides derived from pro-uPA by limited
proteolysis of HLE or V8 protease show a statistically
significant inhibition of invasion in a dose-dependent manner
in an in vitro assay (Figure 8). However, attempts to block
invasion with ATF obtained by plasmin-treated pro-uPA
(ATF[PL]) showed no significant effects. In addition, syn-
Competitor (nM)
*, pro-uPA; o, HMW-uPA; *, ATF[V8]; A, ATF[HLE];
v, uPA2030; v, uPA17-34; * uPA4 43; o, ATF[PL].
Figure 7 Inhibition of binding of FITC-conjugated pro-uPA to U937 cell receptors by uPA polypeptides assessed by flow
cytometry. Pro-uPA (0), HMW-uPA (0), ATF[V8] (A), ATF[HLE] (A), uPA20-30 (V), uPA17-34 (V), uPA4-43 (A),
ATF[PL] (0). Other uPA polypeptides including uPA44-135<52/53>, uPA44-135, uPA47-135, uPAl-135<23/24>, and
uPAl-135<23/24, 35/36> have no inhibition (data not shown). SD<10% in all samples.542 H. KOBAYASHI et al.
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Figure 8 Effects of uPA polypeptides on tumour cell invasion. The HOC-I cells were tested in an in vitro reconstituted basement
membranes invasion assay. The numbers of cells that had attached to the lower surface of the filter at 24 h were used to calculate
invasion. One hundred tLg ml1 l plasminogen was routinely added to the upper chamber and each cell invasion assay was performed
in the presence of plasminogen. Each uPA polypeptide (see Text) and serine proteinase inhibitors (trasylol [500 U ml-'] and
epsilon-aminocapronic acid [E-ACA; 500 tLgml-']) were preincubated with HOC-I cells 60 min before the cells were plated on the
matrigel. Trasylol and E-ACA reduced the invasion by about 70-80% (P< 0.001). The concentration used are not cytotoxic. The
inhibitory effect of the serine proteinase inhibitors was dose-dependent (see Kobayashi et al., 1992b). Control experiments were
carried out in the absence of uPA polypeptides with and without plasminogen (100 ttg ml-). For each experiment three replicates
were performed. Mean and SD of three experiments are shown. The similar results were obtained when these agents were added to
the wells before the cells were seeded into the culture wells (data not shown here).
thetic uPA peptides, uPA20-30 and uPA17-34, had essen-
tially no effect. To investigate the more complete dose rela-
tionship of ATF[HLE] and ATF[V8] on the inhibition of
HOC-I cell invasion, different doses of each uPA polypeptide
were preincubated with HOC-I cells 60 min before the cells
were plated on matrigel. We confirmed that attempts with
ATF[V8] and ATF[HLE], but not ATF[PL], showed a
significant inhibition of invasion in a dose-dependent man-
ner, and gave more of a sense of reproducibility of this
phenomena in replicate experiments (Table I). Also, the data
showed that the dose of 101igml-' used in our experiments
achieved near-maximal effects.
The chemotactic response of the cells was also tested to
determine whether the inhibition of the HOC-I cells ability to
invade was due to the uPA polypeptide inhibiting this re-
sponse (Figure 9). The cells tested here showed a good
chemotactic response in the presence of uPA polypeptides.
These results indicate that there are no effects of uPA
polypeptides on cancer cell chemotaxis, because the cancer
cells are able to migrate to chemoattractants even in the
presence of uPA polypeptides.
In addition, the effects of uPA polypeptides used in the
experiments on HOC-I cell attachment have been studied.
Under optimal conditions, 70% of these cells remain
attached to the well after washing. No inhibition of attach-
ment to fibronectin was seen with any of uPA polypeptides.
The results are shown in Figure 9.
Discussion
The central molecule in the surface pathway for plasminogen
activation appears to be the uPA receptor (Vassalli, et al.,
1985; Blasi et al., 1987; Estreicher et al., 1989). Plasmin,
kallikrein, cathepsin B, L, and thermolysin are known to
cleave pro-uPA at position 158 producing enzymatically
active HMW-uPA, held together by a disulfide bridge
(Gunzler et al., 1982; Ichinose et al., 1986; Gurewich &
Table I Dose-dependent inhibitory activity of ATF[V8], ATF[HLE]
and ATF[PL] on tumour cell invasion
Dose of uPA polypeptides Cells/Field (mean ± SD)'
(gig ml-1)a ATF[V8] ATF[HLE] ATF[PL]
10 19.3 3.7C 18.3 2.3c 27.5 4.5
5 18.9±3.5c 19.4±2.9c 31.7±3.8
2 23.0 2.9d 24.0 0.9d 30.6 ± 2.3
1 28.0 2.2d 26.3 ± 3.7 32.2 ± 4.0
0.5 30.0 2.1 31.2 1.8 33.4 3.5
0.1 33.2 ± 2.6 30.1 ± 1.9 31.0 ± 2.0
0.01 32.4 ± 3.1 33.2 ± 1.7 32.6 ± 2.5
Control 31.6 ± 2.4 31.6 ± 2.4 31.6 ± 2.4
auPA polypeptides were preincubated with HOC-I cells 60 min before
the cells were plated on the matrigel (Figure 8). Control experiments
were carried out in the absence of uPA polypeptides with
plasminogen (100gsgml-'); bFor each experiment three replicates
were performed. Mean and SD of three experiments are shown.
SD<20% in all samples; cP<0.05; dp<0.Ol.
Pannell, 1987; Schmitt et al., 1989; Schmitt et al., 1991;
Kobayashi et al., 1991; Goretzki et al., 1992). Receptor-
bound pro-uPA can be converted to the two-chain form of
uPA-molecule, or alternatively can first be activated by plas-
min or cathepsin B and then bind to the uPA receptor
(Cubellis et al., 1986; Kobayashi et al., 1991). Receptor
molecules could be hidden by the enzymatically inactive
ATF, after the proeolytic cleavage of receptor-bound uPA at
position 135 by plasmin, which might represent a regulatory
mechanism sensing the excess of plasmin at the cell surface
(Cubellis et al., 1986). Under the condition of a high concent-
ration of plasmin near the cell surface, a part of the pro-uPA
produced from the cells could be cleaved in the position of
not only the Lysl58-ILel59 bond and Lysl35-Lysl36 bond
but also of the Lys23-Tyr24 bond and/or Lys35-Lys36 bond
in the GFD before binding to the uPA receptor (Schmitt et
al., 1991; Kobayashi et al., 1992a). These polypeptides withAMINO-TERMINAL FRAGMENTS AND TUMOUR CELL INVASION 543
10 10 10 10 10 10 10 10 10 10 10 10
,ug/mI ,ug/mI ,ug/mI ,ug/mI ,ug/mI rLg/mI
Control
* ATF [V8]ATF [HLEI ATF [PL] uPA4-43 uPA20_30 uPA17-34
, Chemotactic response; _ , Cell attachment.
*Add 100 jg/ml plasminogen.
Figure 9 Effects of uPA polypeptides on tumour cell attachment and chemotaxis. chemotactic response (Cells/Field; %);
_, cell attachment (Attached cells/Field; 0). SD<20% in all samples.
Chemotactic assay: The chemotactic assay was conducted in a similar fashion without coating of matrigel. The number of cells on
the bottom surface of the filter in the absence of uPA polyeptides were designated at 100%. Cell attachment assay: HOC-I cells
were seeded on fibronectin in the presence and absence of uPA polyeptides. After 2 h later, 70% of the cells attached to the wells in
the absence of uPA polypeptides (Control). These values were designated at 100%. Each experiment was performed in the presence
of plasminogen (100 .g ml- ').
the cleavage occurring in the GFD can not bind to uPA
receptor on U937 cells any more, providing an additional
feedback mechanism of regulation of uPA binding to the
receptor (Kobayashi et al., 1992a).
Our preliminary study indicates that (1) ovarian cancer
derived HOC-I cells used in this study have uPA molecules
on their cell surfaces and most of the cell-associated uPA on
the cell surfaces are enzymatically inactive pro-uPA, that (2)
pro-uPA is bound to a specific surface receptor that is
incompletely saturated, that (3) cell-associated pro-uPA can
be converted to HMW-uPA by plasmin and cathepsin B, and
that (4) its activity can be inhibited by an antibody against
B-chain of uPA (Kobayashi et al., 1992b). We attempted to
isolate uPA polypeptides with intact GFD from proteinase-
treated pro-uPA to determine whether uPA polypeptides can
inhibit HOC-I cell invasion in an in vitro assay, when all
membrane receptor sites are saturated by enzymatically inac-
tive uPA fragments such as intact GFD or ATF. The
significance of the expression of cell surface uPA activity on
invasive potential was examined by saturation of free uPA
receptor with enzymatically inactive uPA polypeptides. uPA
polypeptides derived from pro-uPA by limited proteolysis of
HLE or V8 protease significantly inhibit invasion in a dose-
dependent manner. This inhibition may correlate with the
quantities of uPA polypeptides available to saturate uPA
receptors. Furthermore, we conclude that the mode of action
of this peptide is not due to inhibition of cancer cell attach-
ment and cell chemotaxis. The above mentioned uPA
polypeptides appeared capable of blocking invasion not only
when they were added with the cells but also when they were
preadsorbed on to the basement membrane matrigel (data
not shown). On the contrary ATF obtained from plasmin-
treated uPA (ATF[PL]) did not affect the invasive potential
of the cells. Also, synthetic uPA peptides had essentially no
effect, indicating that both an intact peptide sequence 20-30
and the conformation of GFD are prerequisites for binding
of uPA-molecules (Schmitt et al., 1991) and for inhibition of
tumour cell invasion.
Various investigators (Liotta et al., 1980; Thorgeirsson et
al., 1982; Ostrowski et al., 1986; Bergman et al., 1986; Naka-
jima et al., 1987; Reich et al., 1988; Hearing et al., 1988;
Cajot et al., 1989; Baker et al., 1990; Ellis et al., 1990) have
shown that tumour cells may express surface-associated uPA
activity and that inhibition of this activity by specific
antibodies or proteinase inhibitors leads to a decrease in the
invasive potential of tumour cells.
The use of antibodies in therapy of humans is highly
restricted. Our data indicate that enzymatically inactive
receptor-bound uPA polypeptides can also lead to a decrease
in the invasive potential of this tumour cell line and would be
worth testing in livo. The uPA receptor on HOC-I cells
would be hidden by the enzymatically inactive uPA polypep-
tides, which leads to a decrease in a proteolytic action on
tumour cell surfaces.
The incompleteness with which the competitive receptor-
bound uPA polypeptides block invasion indicates that uPA is
not sufficient in invasion mechanisms, suggesting that HOC-I
cells have a significant uPA/plasmin-independent proteinase
activity (Kobayashi et al., 1992b). We did not examine addi-
tional evidence for the participation of other proteinases such
as metalloproteinases. Other explanations are that (1) pro-
uPA/uPA-bound receptors are not reoccupied by exogenous
uPA fragments/peptides, that (2) binding sites of receptor-
bound uPA polypeptides, which were added exogenously.
may be cleaved by trace contamination of plasmin in the
plasminogen preparation, and that (3) the affinity of uPA
polypeptides to uPA receptors is lower than that of pro-uPA/
HMW-uPA produced by cancer cells, suggesting that uPA
receptors may be reoccupied by uPA-molecules released from
tumour cells. Notwithstanding these limitations, the present
study strongly argues for a role of the cell-associated uPA/
receptor-system in facilitating the in vitro invasion of ovarian
cancer cells.
The authors wish to acknowledge the extremely helpful critiques of
Dr N. Kanayama (Hamamatsu University School of Medicine).
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